Found 696 All Conditions trials
A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is an open-label, non-randomized trial that will be conducted at three clinical sites. The subject population will be patients undergoing transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC) at Thomas Jefferson University, The University of California, San Diego, and University of Pennsylvania. Patients will receive a contrast-enhanced …
This is a Phase II single-arm, single-site, open label clinical trial with r/r HL patients, aimed to determine whether a RadVax approach using low-dose RT added to nivolumab can improve response among patients who do not achieve a CR to nivolumab alone. The long-term goal is to develop an effective …
The trial involves an investigational device (not approved by the FDA) for subjects who have an aneurysm (bulge), dissection (tear) or a penetrating ulcer (bubble) of the descending aorta that involve an artery (main blood vessel in your body). The subject must need to have one of their blood vessels …
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body's immune system to attack any cancer …
This non-therapeutic, multi-center LTFU study involves up to 15 years post-infusion monitoring of subjects who have been exposed to lentivirus-mediated gene transfer in Adaptimmune clinical studies. Subjects will undergo clinical evaluation with careful attention to adverse events possibly related to gene transfer/lentivirus-induced diseases. Blood samples will be collected. Subjects will …
The main aims of this study are to test the safety of up to 4 different doses of UCART19, and to identify the best dose of UCART19, by measuring what has happened to the leukemia cells at day 28 (28 days after the administration of UCART19), day 84 (84 days …
The purpose of this study is to see if JNJ-61186372 is safe and useful for treating patients with advanced, metastatic, non-small cell lung cancer (NSCLC).
